FLEX, a real-world evidence full transcriptome study of 30,000 patients with early-stage breast cancer

被引：0
|
作者：
Brown, Eric Allen
Gold, Linsey P.
Gray, Carl R.
Marks, Douglas Kanter
Thomas, Vibha Taneja
Santillan, Alfredo A.
Singleton, Ciera S.
Audeh, M. William William
机构：
[1] Comprehens Breast Care, Troy, MI USA
[2] Utah Hem Onc, Ogden, UT USA
[3] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[4] Texas Oncol, Flower Mound, TX USA
[5] Texas Oncol PA, San Antonio, TX USA
[6] Agendia Inc, Irvine, CA USA
[7] Agendia, Irvine, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS621
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real-world retrospective study of early-stage prostate cancer at a Portuguese Comprehensive Cancer Centre: The PEarlC study
    Braga, Isaac
    Goncalves-Monteiro, Salome
    Calisto, Rita
    Rangel, Marta
    Medeiros, Eduardo
    Cunha, Jose Luis
    Rosinha, Alina
    Oliveira, Angelo
    Fialho, Ana Cristina
    Santos, Susana
    Redondo, Patricia
    Bento, Maria Jose
    ONCOLOGY LETTERS, 2024, 28 (02)
  • [32] A prospective, real-world study of treatment patterns in early-stage breast cancer (ESBC) patients (pts) at high risk for febrile neutropenia (FN).
    Tzivelekis, Spyridon
    Stryker, Scott
    Klippel, Zandra Karina
    Sheldon, Wayne
    Li, Yanli
    Chandler, David
    Nagarajan, Arun
    Reiner, Maureen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Real-World evidence for Pembrolizumab-based neoadjuvant chemotherapy in early-stage triple negative breast cancer: a single institution experience
    Al-Awadhi, Aydah
    AlShebli, Mouza
    Wahba, Lina
    Younis, Tallal
    CANCER RESEARCH, 2024, 84 (09)
  • [34] A prospective, international, observational, real world evidence database, and collaborative platform for Investigator-Initiated Studies in Early-Stage Breast Cancer tested with MammaPrint and BluePrint the FLEX Study
    Alberty-Oller, J. J.
    Riley, Lee
    Samiian, Laila
    Thayer, Sarah
    Aseyev, Olexiy
    Tedesco, Karen
    Poillucci, Victoria
    Audeh, William
    Jelovac, Danijela
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2024, 84 (09)
  • [35] Adjuvant taxane therapy for early-stage breast cancer: A real-world comparison of chemotherapy regimens in Ontario.
    Torres, Sofia
    Trudeau, Maureen E.
    Eisen, Andrea
    Earle, Craig
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Real-world outcomes of neoadjuvant treatment for HER2 positive early-stage breast cancer.
    Naik, Hiten
    Gelmon, Karen A.
    Gondara, Lovedeep
    Diocee, Rekha M.
    Speers, Caroline
    Yerushalmi, Rinat
    Lohrisch, Caroline A.
    LeVasseur, Nathalie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Real-World Outcomes with the KEYNOTE-522 Regimen in Early-Stage Triple-Negative Breast Cancer
    Connors, Casey
    Valente, Stephanie A.
    ElSherif, Ayat
    Escobar, Paula
    Chichura, Anna
    Kopicky, Lauren
    Roesch, Erin
    Ritner, Julie
    Mcintire, Patrick
    Wu, Yueqi
    Tu, Chao
    Lang, Julie E.
    ANNALS OF SURGICAL ONCOLOGY, 2025, 32 (02) : 912 - 921
  • [38] Clinical trial representativeness and treatment intensity in a real-world sample of women with early-stage breast cancer.
    Caston, Nicole E.
    Williams, Courtney
    Franks, Jeffrey
    Aswani, Monica S.
    Azuero, Andres
    Gidwani, Risha
    Rocque, Gabrielle Betty
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence
    Jovanoski, Nick
    Bowes, Kathleen
    Brown, Audrey
    Belleli, Rossella
    Di Maio, Danilo
    Chadda, Shkun
    Abogunrin, Seye
    LUNG CANCER MANAGEMENT, 2023, 12 (03)
  • [40] Treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence
    Kathleen Bowes
    Nick Jovanoski
    Audrey E. Brown
    Danilo Di Maio
    Rossella Belleli
    Shkun Chadda
    Seye Abogunrin
    Medical Oncology, 40
12345